STL-MESHS
STL
(Savoirs, Textes, Langage), UMR CNRS 8163,
Université de Lille : a multidisciplinary research
laboratory (linguistics, philology, philosophy and
history of science). The strength of the linguistich
research is consolidated thanks to the collaboration
between theoretical linguists and NLP researchers. For
several years, STL members have been involved in
projects dedicated to the biomedical field, including
works on readability and acquisition.
STL is assisted by the USR CNRS 3185 MESHS (Maison
Européenne des Sciences de l'Homme et de la Société) in
managing and promoting results and knowledge.
LIMSI
The
Computer Sciences Laboratory for Mechanics and
Engineering Sciences (LIMSI): a CNRS laboratory
(UPR 3251) with 250 members (120 of which are
permanent). The ILES team is well-know in the NLP
field. Within this group, different topics are
addressed, among which information extraction,
question answering, corpus linguistics, error analysis
and readability. LIMSI members were involved in
several projets (such as the Quæro program or ANR
projects) and NLP competitions.
LEPS
Laboratoire de Pédagogie de la Santé (EA3412
LEPS), Université Paris 13. Since 1977, LEPS
members address research questions related to health
education and practice, systemic problems of chronic
diseases, role and relations between medical staff and
patients, modern medical practice. LEPS researchers
are especially involved in health education, the
education continuum concerned with primary, secondary
and tertiary prevention : education for health, first
aid, and therapeutic education.
AFH
Haemophilia covers several genetic pathologies,
severe and rare, that affect over 6,000 persons in
France. If other very close pathologies (such as
advanced forms of Willebrand disease or various
coagulation disorders) are also taken into account,
more ahtn 15,000 persons are affected in France.
Founded in 1955, the
Association
Française des Hémophiles (AFH) provides
information, help and protection to persons
suffering from haemophilia, Willebrand disease
and rare coagulation disorders. The association
obtained the official approval from the
Ministère de la Santé in 1968 and is allowed to
represent patients since 2006. It represents
patients and their families at legal health
institutions and authorities, national or
regional. In order to stay close to its members,
AFH has created regional committees all over the
French territory, metropolitan or overseas.
The association actively promotes the
improvement of patients' knowledge, as well as
research on treatments and medical care of rare
coagulation disorders. The priority is focused
on the reliability of treatments. AFH works on
four main goals:
- developing therapeutic education of patients,
- supporting regions and their committees,
- taking part in international actions,
- creating foundations for research activities within the association.
Several steps have been taken to increase the
visibility and importance of AFH:
- AFH is member of the World Federation of
Hemophilia and of the European Haemophilia
Consortium;
- AFH participates in several
trans-association networks, such as CISS
(Collectif interassociatif sur la
santé);
- AFH is an active member of organisms
related to public health and medical research
: member of the steering board of
antihaemophilic drugs in the Agence
Nationale de Sécurité du Médicament et des
produits de santé (ANSM), member of the
Institut de Veille Sanitaire (InVS),
member of the FranceCoag network and
administrator of the Établissement Français
du Sang (EFS);
- AFH is a member of the CRMH's (Centre
de Référence de l'hémophilie et autres
Maladies Hémorragiques) steering board,
the CRMW's (Centre national de Référence de
la Maladie de Willebrand) steering board
and the ONIAM's (Office National
d'Indemnisation des Accidents Médicaux)
orientation board.
The association has a scientific board that
meets once a year at a national level and that
gathers health professionals, patients and their
families. AFH publishes a journal, which created
the link with its members and provides
associative, medical, social and legal
information of haemophilia and Willebrand
disease. The association is composed of
employees and active volunteers, with 23
regional boards that work closely with the
CTH (Centre de Traitement de
l'Hémophilie).
Synapse Développement
Synapse
Développement is a software house. For 20
years, it has been the leader in the area of
text correction with its product Cordial (a
software or online web application). Synapse
Développement also maintains Cordial Dico, a
French reference dictionary (definitions,
synonyms, difficulties...). Synapse
Développement provides solutions for stylistic
and semantic analysis. The company designs
software for individuals (over 30,000 customers)
and professionals (Microsoft, Amazon, Le
Parisien, AFP, Pages Jaunes, Reverso, etc.). One
of its objectives in this project is to adapt
and exploit these various resources to create a
prototype for text analysis and
simplification. Synapse's R&D team is composed
of linguists, computer scientists and NLP
experts.
